12,002 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Trifecta Capital Advisors LLC

Key Points

• Trifecta Capital Advisors acquired 12,002 shares of Thermo Fisher Scientific worth approximately $6.0 million, while institutional investors collectively own 89.23% of the company.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 EPS and $11.99 billion in revenue, with revenue rising 10.5% year over year. The company set fiscal 2026 EPS guidance at $24.93–$25.33.
• The stock has a “Moderate Buy” consensus rating and an average analyst price target of $619.41, although insiders sold more than 52,000 shares worth approximately $30.6 million over the past 90 days.

Trifecta Capital Advisors LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 12,002 shares of the medical research company's stock, valued at approximately $6,017,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Legacy Wealth Managment LLC ID boosted its stake in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the last quarter. Allied Private Wealth LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $26,000. High Note Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after purchasing an additional 29 shares during the last quarter. Swiss RE Ltd. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Finally, JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $28,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.0%

Shares of TMO opened at $588.17 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The firm has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock's fifty day simple moving average is $529.37 and its 200 day simple moving average is $508.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is presently 10.11%.

Insider Activity

In related news, CAO Joseph R. Holmes sold 420 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on TMO. Royal Bank Of Canada lifted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research note on Friday, July 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 price objective on the stock. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Finally, HSBC lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and cut their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source